A Red Hand Letter (Rote-Hand-Brief) is a short-term safety communication in Germany addressed to healthcare professionals regarding new findings relevant to the therapy of a medicinal product. It is utilized when the information is not yet included in the Summary of Product Characteristics (SmPC) and necessitates a change in prescribing behavior or immediate therapeutic action.
Occasion and Content in German Practice
The BfArM cites typical occasions as a new contraindication, a new warning, or the recall of a preparation or batch due to medical risk, a significant quality defect, or a risk of confusion. A letter may also serve to remind of existing contraindications and warnings if these are not sufficiently observed in daily healthcare. It is characterized by the Red Hand symbol.
Safety information must reach healthcare professionals rapidly because incorporating a change into the SmPC and Package Leaflet takes time, and these documents are not noticed by all users simultaneously. Many Red Hand Letters follow European risk assessment or signal procedures; however, the BfArM can also demand their distribution on a purely national basis. Pharmaceutical companies distribute the communication as a risk-minimization measure under their own responsibility.
The letter addresses members of the healthcare professions and focuses on the specific adjustment required for application. Its effectiveness is therefore not based on a complete representation of the entire safety profile, but on the clear communication of the new risk, the affected medicinal products, and the required measure. The SmPC remains the authoritative product document, while the Red Hand Letter enables the urgent transition to the amended practice.
For medicinal products within the jurisdiction of the Paul Ehrlich Institute, the corresponding safety information is published there. The letters available at the BfArM refer only to medicinal products within its own jurisdiction. For healthcare professionals and study organizations, this departmental jurisdiction is relevant so that a search for risk information is not erroneously restricted to a single publishing body.
Distinction from Information Letters and DHPC
An Information Letter is not the urgent Red Hand Letter. It may inform healthcare professionals about an extension of marketing authorization or qualitative changes, for example, without resulting in an immediate influence on therapy; it therefore does not bear the Red Hand symbol. The classification is based on the target group’s need for action, not on whether a letter contains product-related news at all.
The European Direct Healthcare Professional Communication, or DHPC, is the umbrella term for direct communication to individual members of the healthcare professions to enable them to adapt their actions in connection with a medicinal product. In European procedures, both Red Hand Letters and Information Letters are referred to as DHPCs. The Red Hand Letter is thus the specific German implementation for particularly rapid safety information that influences therapy, not the translation of every DHPC.
Coordination and Objective Presentation
Planned safety communications must be coordinated with the competent national authorities regarding content and the target audience. The text must be objective. It must not contain promotional information and should clearly separate the action necessary for safe use from other product information. Coordination therefore concerns not only the choice of words but also the question of which healthcare professionals the measure must actually reach.
The legal basis for the obligation to inform is Section 11a(2) of the German Medicines Act (AMG). According to this, pharmaceutical companies must inform healthcare professionals about changes to the SmPC that are significant for therapy. In appropriate cases, the Red Hand Letter bridges the period during which the updated product information is not yet available or has not yet been sufficiently received.
Its format thus serves as a targeted safety intervention and not as a routine update of product news.
Relevance for clinical trials
If a study site receives a Red Hand Letter regarding a medicinal product used in the study, simply filing the letter is insufficient. The sponsor and investigator must review the new safety information against the protocol, Investigator’s Brochure, informed consent documents, safety management, and the current care of the participants. If a change in protective measures or application results, the respective study documents and the communication to study sites must be adapted in a traceable manner.
Full-service CROs like Mediconomics support Red Hand Letters through structured impact analysis for ongoing studies, the coordination of Safety, Regulatory Affairs, and Monitoring, as well as the creation of study-related information packages for study sites. They document which products, countries, sites, and documents are affected and accompany the controlled implementation of the required risk minimization.
Frequently Asked Questions (FAQ)
When is a Rote-Hand-Brief (DHPC) indicated instead of an informational letter?
A Rote-Hand-Brief is indicated when new information necessitates a change in prescribing behavior or when there is a need for action that directly influences therapy. In contrast, an informational letter concerns communications without such immediate therapeutic impact.
Are Rote-Hand-Briefs in Germany purely national communications?
No. The vast majority arise from European risk assessment or signaling procedures. However, the BfArM can also request a Rote-Hand-Brief in a national context.
May a Rote-Hand-Brief highlight product benefits?
No. The BfArM requires an objective presentation of information; promotional statements are not permitted. The letter serves the purpose of risk communication rather than product advertising.
Regulatory References
- Section 11a(2) of the German Medicines Act (AMG) – obligates pharmaceutical companies to provide information on therapy-relevant changes to the SmPC.
- EMA, GVP Annex I Definitions – defines the DHPC as direct communication to adapt professional practice.
- EMA, GVP Module XVI – covers risk-minimization communication measures and their selection.
- BfArM, FAQ on Red Hand Letters and Information Letters – describes occasions, distinction, and German coordination practice.